NNC0721-8060
DrugNNC0721-8060 will be administered subcutaneously.
NCT Number: NCT07767175
The purpose of the study is to find out if NNC0721-8060 is safe and how it works in people living with overweight or obesity.
Interested in participating?
Request Info18 year–55 year
All sexes
Interventional
Phase 1
ICON Early Phase Services, LLC, Lenexa, Kansas, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
NNC0721-8060 will be administered subcutaneously.
Semaglutide will be administered subcutaneously.
Placebo will be administered subcutaneously.
Time frame: From Day 1 to Day 36
Measured as number of events.
Time frame: From Day 1 to Day 57
Measured as number of events.
Time frame: From Day 1 to Day 85
Measured as percentage change in body weight.
Time frame: From Day 1 to Day 36
Measured as hour nanomoles per litre (h*nmol/L).
Time frame: From Day 1 to Day 36
Measured as nanomoles per litre (nmol/L).
Time frame: From Day 1 to Day 57
Measured as h*nmol/L.
Time frame: From Day 1 to Day 57
Measured as nmol/L.
Time frame: From Day 1 to Day 113
Measured as h*nmol/L.
Time frame: From Day 1 to Day 113
Measured as nmol/L.
Time frame: From Day 1 to Day 113
Measured as number of events.
Contact information is provided by the study sponsor or research team.
Novo Nordisk A/S
Industry
A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0721-8060 in Healthy Adult Participants Living With Overweight or Obesity
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07595549
Body Weight, Diabetes Mellitus
Modesto, California, United States
View Trial DetailsNCT06044935
Body Weight, Nutrition Disorders
Bethesda, Maryland, United States
View Trial DetailsNCT07745504
Body Weight, Nutrition Disorders
Conyers, Georgia, United States
View Trial DetailsNCT07662122
Body Weight, Nutrition Disorders
Birmingham, Alabama, United States
View Trial Details